Intuitive Surgical Inc (NASDAQ: ISRG)

$438.10 ▼ -1.94 (-0.44%)
As of May 22, 2026 04:00 PM
Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0001035267
Market Cap 156.17 Bn
P/E 52.64
P/S 14.76
Div. Yield 0.00
ROIC (Qtr) 0.00
Revenue Growth (1y) (Qtr) 22.96
Add ratio to table...

About

Intuitive Surgical, Inc. provides a comprehensive ecosystem of robotic assisted surgical systems, instruments and accessories, customer learning and support services, and a digital platform that delivers actionable insights across the care continuum. The company's core products include the da Vinci surgical systems for a broad range of minimally invasive procedures and the Ion endoluminal system for minimally invasive lung biopsies. It operates in the medical technology industry, specifically within the robotic assisted surgery and diagnostic sectors....

Read more

Investment thesis

Bull case

  • Intuitive’s positioning as a leader in minimally invasive surgery remains in its nascent phase, with global procedure volumes still expanding at double‑digit rates. The company’s strategic emphasis on new indications—cardiac, thoracic, colorectal, and nipple‑spare mastectomy—provides a clear path to further market penetration. Early adopters across Europe, Japan, and emerging markets are reporting positive outcomes and efficient learning curves, suggesting that the regulatory and reimbursement environments are aligning favorably. As the robotic platform integrates advanced features such as force feedback and AI‑driven case insights, surgeons are likely to experience measurable improvements in precision and patient recovery, reinforcing demand for future upgrades.
  • Digital ecosystems, epitomized by MyIntuitive Plus, are creating incremental revenue streams beyond core system sales. The platform bundles telepresence, simulation, and data analytics, allowing hospitals to derive continuous performance insights while justifying subscription fees. Although the rollout initially included a free year, the high renewal rates expected from early users will convert into recurring income as adoption deepens. This shift to subscription aligns with broader industry trends toward software as a service, adding stability to Intuitive’s revenue mix. Moreover, the integration of force‑feedback instruments with the digital layer could unlock cross‑sell opportunities that reinforce the platform’s value proposition.
  • The refurbished Xi and XIR programs are unlocking new customer segments that would otherwise remain price‑sensitive. By offering lower‑cost, high‑quality alternatives, Intuitive extends its reach into ambulatory surgery centers and smaller hospitals, accelerating total market penetration. The refurbishment strategy leverages existing manufacturing and supply chains, keeping capital expenditures lean while driving volume. It also mitigates the risk of market saturation in high‑margin segments by broadening the base of users who can afford the technology. Early data shows steady utilization growth within the ASC ecosystem, a trend that portends a broader shift toward outpatient robotic care.
  • Intuitive’s robust cash position—over $9 billion—provides a buffer for continued investment in R&D, market expansion, and share repurchases. The company’s disciplined capital allocation strategy has yielded high free cash flow and a history of consistent stock buybacks, supporting long‑term shareholder value. This financial resilience positions Intuitive to absorb short‑term macroeconomic pressures, such as tariff adjustments and potential reimbursement volatility, without compromising growth initiatives. Additionally, the company’s global footprint, with production centers in Mexico and China, offers diversified supply chains that can mitigate geopolitical disruptions.
  • The company’s operational efficiency initiatives have resulted in a steady climb in operating margin, projected to stay within the 67–68% range for 2026. The focus on industrial scale, manufacturing optimization, and product quality has effectively counterbalanced the cost impacts of tariffs and the integration of newer platform mixes. The continued margin improvement signals that Intuitive’s cost structure is resilient to price erosion and can absorb future competitive pressure. Moreover, the company’s emphasis on high‑utilization scenarios—such as after‑hours procedures and IDN deployment—enhances overall profitability by maximizing system usage.
Read more

Bear case

  • Intuitive’s financial performance, while robust, is increasingly exposed to tariff fluctuations and trade policy uncertainty. The company’s dependency on Mexican production for the majority of instruments introduces vulnerability to exchange rate swings and potential supply chain disruptions tied to U.S.–Mexico relations. Even modest tariff increases can erode operating margins, and the company’s forecast includes a 1.2% revenue hit from tariffs in 2026, indicating that margin pressures could tighten if geopolitical tensions persist.
  • Competitive dynamics in China and other emerging markets pose a significant threat to Intuitive’s market share. Local competitors, often leveraging lower pricing and provincial procurement preferences, have intensified tender battles, reducing win ratios. The company’s reliance on a single system—despite its modular upgrades—may limit flexibility for hospitals facing strict cost controls or seeking more affordable alternatives. A sustained loss of traction in these high‑growth markets could slow global procedure growth and undermine the company’s expansion narrative.
  • Intuitive’s capital intensity and high operating expense trajectory could dampen future profitability. The company’s 11–15% projected operating expense growth, driven by direct‑to‑consumer initiatives and distributor acquisitions, may offset the gains from higher margins and expansion. Moreover, the shift to a more service‑heavy revenue model, while providing recurring income, introduces fixed costs that must be carefully managed to avoid margin compression. If operating costs outpace revenue growth, the company’s ability to maintain its target gross margin range could be compromised.
  • The adoption of newer indications such as cardiac and thoracic procedures remains uncertain and could delay the anticipated revenue upside. Regulatory clearance for cardiac instrumentation and force‑feedback integration is still in early phases, and the pathway to widespread clinical adoption is lengthy. Delays in reimbursement approvals or lackluster surgeon uptake could limit the realized value of these high‑investment product launches, creating a gap between projected and actual growth.
  • The market for lower‑acuity cases is shifting toward laparoscopy, and Intuitive’s high‑price, high‑complexity platform may struggle to compete in this segment. Although the company offers refurbished systems to penetrate this market, the cost advantage remains modest compared to advanced laparoscopic systems. Hospitals and surgeons increasingly weigh procedural cost against outcomes, and if the marginal benefit of robotic surgery is perceived as limited for low‑complexity cases, adoption may stall or reverse.
Read more

Geographic Distribution Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 156.17 Bn 52.64 14.76 -
2 BDX Becton Dickinson & Co 41.51 Bn 29.74 1.94 17.28 Bn
3 RMD Resmed Inc 30.43 Bn 20.13 5.50 0.26 Bn
4 WST West Pharmaceutical Services Inc 22.78 Bn 42.07 7.07 0.20 Bn
5 SOLV Solventum Corp 13.39 Bn 9.37 1.62 5.08 Bn
6 COO Cooper Companies, Inc. 12.33 Bn 31.01 2.97 2.50 Bn
7 ALGN Align Technology Inc 11.65 Bn 27.31 2.84 -
8 BAX Baxter International Inc 9.81 Bn -72.70 0.91 9.46 Bn